Valuation: Astellas Pharma Inc.

Market Cap 3,896B 24.06B 21.07B 19.45B 18.16B 34.19B 2,275B 34.97B 234B 90.36B 1,122B 90.36B 88.38B P/E 2027 *
11.2x
P/E 2028 * 11.9x
Enterprise Value 3,820B 23.59B 20.65B 19.07B 17.8B 33.52B 2,230B 34.28B 229B 88.58B 1,100B 88.58B 86.64B EV / Sales 2027 *
1.7x
EV / Sales 2028 * 1.69x
Free-Float
98.88%
Yield 2027 *
3.71%
Yield 2028 * 3.83%
1 day+0.18%
1 week+1.97%
Current month-4.73%
1 month+0.05%
3 months-14.99%
6 months+3.92%
Current year+3.92%
1 week 2,128
Extreme 2128
2,204
1 month 2,041
Extreme 2041
2,275
Current year 2,041
Extreme 2041
2,717
1 year 1,365
Extreme 1365
2,717
3 years 1,243.5
Extreme 1243.5
2,717
5 years 1,243.5
Extreme 1243.5
2,717
10 years 1,243.5
Extreme 1243.5
2,717
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2023
Director of Finance/CFO 54 01/11/2023
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 10/02/2023
Director/Board Member 63 01/06/2019
Director/Board Member 58 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
+0.18%+1.97%+53.55%+1.21% 24.02B
-1.90%+9.96%+56.16%+159.57% 1,097B
-1.02%+7.39%+68.08%+55.11% 622B
-0.60%+7.91%+36.48%+88.03% 449B
-1.71%+6.34%+29.51%+24.01% 334B
-0.35%+5.08%+41.11%+26.64% 294B
+0.63%+3.14%+32.37%+41.44% 286B
+0.96%+2.91%-27.96%-42.39% 213B
-0.34%+4.06%+29.33%+62.64% 195B
-0.93%+0.59%+13.46%+63.22% 157B
Average -0.52%+6.08%+33.21%+47.95% 367.08B
Weighted average by Cap. -0.96%+8.66%+42.14%+78.91%

Financials

2027 *2028 *
Net sales 2,249B 13.89B 12.16B 11.23B 10.48B 19.73B 1,313B 20.18B 135B 52.15B 648B 52.16B 51.01B 2,079B 12.84B 11.24B 10.38B 9.69B 18.25B 1,214B 18.66B 125B 48.22B 599B 48.22B 47.16B
Net income 346B 2.14B 1.87B 1.73B 1.61B 3.03B 202B 3.1B 20.77B 8.02B 99.61B 8.02B 7.84B 327B 2.02B 1.77B 1.63B 1.53B 2.87B 191B 2.94B 19.66B 7.59B 94.28B 7.59B 7.42B
Net Debt -76.78B -474M -415M -383M -358M -674M -44.83B -689M -4.61B -1.78B -22.12B -1.78B -1.74B -391B -2.42B -2.12B -1.95B -1.82B -3.43B -228B -3.51B -23.5B -9.07B -113B -9.07B -8.87B
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
30/06/26 ¥2,175.00 +0.18% 9,968,900
29/06/26 ¥2,171.00 +1.21% 10,716,900
26/06/26 ¥2,145.00 -0.09% 6,216,800
25/06/26 ¥2,147.00 -0.58% 4,672,000
24/06/26 ¥2,159.50 +1.24% 5,998,200
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
2,171.00JPY
Average target price
2,384.62JPY
Spread / Average Target
+9.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4503 Stock